Navidea Biopharmaceuticals, Inc.

NAVB

US63937X2027

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 11:31:52 2024-04-29 am EDT			5-day change	1st Jan Change
0.035 ^USD	-8.14%		-20.45%	-36.59%

2023	Navidea Biopharmaceuticals, Inc. announced that it expects to receive $0.75 million in funding	CI
2023	Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Navidea: Q2 Earnings Snapshot

August 15, 2022 at 08:40 am EDT

DUBLIN, Ohio (AP) _ Navidea Biopharmaceuticals Inc. (NAVB) on Monday reported a loss of $3 million in its second quarter.

On a per-share basis, the Dublin, Ohio-based company said it had a loss of 10 cents.

The biopharmaceutical posted revenue of $57,500 in the period. Its adjusted revenue was $58,000.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NAVB at https://www.zacks.com/ap/NAVB

Latest news about Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc. announced that it expects to receive $0.75 million in funding	Nov. 26	CI
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Navidea Biopharmaceuticals, Inc.(OTCPK:NAVB) dropped from S&P TMI Index	23-10-11	CI
Sector Update: Health Care	23-10-06	MT
Top Midday Decliners	23-10-06	MT
Navidea Biopharmaceuticals Says NYSE American Panel Upheld Delisting Decision	23-10-06	MT
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Navidea Biopharmaceuticals, Inc. Announces Resignation of Malcolm G. Witter as Director, Member of the Audit Committee and Compensation, Nominating and Governance Committee of the Board	23-08-08	CI
Navidea Biopharmaceuticals, Inc. Announces Executive Changes	23-07-28	CI
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer	23-07-27	CI
Navidea Biopharmaceuticals, Inc. Announces Board Changes	23-07-13	CI
Navidea Biopharmaceuticals Confirms Rejection of ProPhase Labs' Proposal to Buy Some of Its Assets	23-06-30	MT
ProPhase Labs Says Offer to Acquire Certain Navidea Biopharmaceuticals' Assets Rejected	23-06-29	MT
ProPhase Labs, Inc. cancelled the acquisition of Certain Assets from Navidea Biopharmaceuticals, Inc. for $7 million.	23-06-28	CI
Sector Update: Health Care Stocks Steady Late Friday	23-06-16	MT
Sector Update: Health Care	23-06-16	MT
Navidea Biopharmaceuticals Gets $7.5 Million Payment From Cardinal Health	23-06-16	MT
Navidea Biopharmaceuticals Notified of Non-Compliance With NYSE American Listing Rule	23-06-05	MT
Navidea Biopharmaceuticals, Inc. Announces Board Changes	23-06-01	CI
Navidea Biopharmaceuticals Sells Preferred Shares Worth $1.1 Million	23-05-23	MT
Navidea Biopharmaceuticals, Inc. announced that it expects to receive $1.1 million in funding	23-05-21	CI
Navidea Biopharmaceuticals Promotes Michael Sherman Blue to Chief Medical Officer	23-05-11	MT
Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer	23-05-11	CI
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Navidea Biopharmaceuticals Intends to Sell Cardinal Milestone Payment	23-04-27	CI

Chart Navidea Biopharmaceuticals, Inc.

Duration

Period

More charts

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. The Companyâs business is focused on two primary types of drug products, such as diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform, and therapeutic development programs, including therapeutic applications of its Manocept platform. It has developed processes for producing the first four therapeutic Manocept immuno-construct series, the Manocept doxorubicin (MAN-DOX) series, which is designed to specifically target and kill or modify activated CD206+ macrophages by delivering doxorubicin, a Manocept paclitaxel series (MAN-PAC), and a Manocept Bisphosphonate series (MAN-BIS).

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NAVIDEA BIOPHARMACEUTICALS, INC.	-36.59%	3.81M
IQVIA HOLDINGS INC.	+1.77%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+12.24%	41.34B
CELLTRION, INC.	-8.83%	26.59B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.12B
MEDPACE HOLDINGS, INC.	+30.56%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.35%	11B